Can a simple blood test predict cancer risk from radiation therapy?

This study is for people with neuroendocrine tumors who are about to receive or have already received peptide receptor radionuclide therapy (PRRT). Researchers want to find out if certain genetic changes in the blood can predict who might later develop myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), two types of blood cancer. About 45 participants will give blood samples over several years to look for these genetic markers. The goal is not to treat the blood cancers, but to better understand the risks and improve patient care.